4.5 Article

Cross-sectional study on exhaled nitric oxide in relation to upper airway inflammatory disorders with regard to asthma and perennial sensitization

期刊

CLINICAL AND EXPERIMENTAL ALLERGY
卷 52, 期 2, 页码 297-311

出版社

WILEY
DOI: 10.1111/cea.14019

关键词

asthma; exhaled nitric oxide; FeNO; nasal polyposis; population-based; rhinitis

资金

  1. Medical Research Council [92091]
  2. Australia: National Health & Medical Research Council
  3. Belgium: Antwerp South, Antwerp City-Research Foundation Flanders (FWO) [G.0.410.08.N.10]
  4. Estonia: Estonian Ministry of Education [Tartu-SF0180060s09]
  5. Estonian Research Council [562]
  6. France: Ministere de la Sante, Programme Hospitalier de Recherche Clinique (PHRC)
  7. Bordeaux-INSERM U897 Universite Bordeaux Segalen
  8. Grenoble-Comite Scientifique AGIRadom 2011
  9. Paris-Agence Nationale de la Sante, Region Ile de France, domaine d'interet majeur (DIM)
  10. Germany: Erfurt-German Research Foundation [HE 3294/10-1]
  11. Hamburg-German Research Foundation [MA 711/6-1, NO 262/7-1]
  12. Iceland: Reykjavik-The Landspitali University Hospital Research Fund
  13. Iceland: Iceland Research Fund
  14. Iceland: ResMed Foundation, California, USA
  15. Iceland: Orkuveita Reykjavikur (Geothermal plant), Vegageroin (The Icelandic Road Administration (ICERA)
  16. Italy: Italian Ministry of Health
  17. Italy: Chiesi Farmaceutici SpA
  18. Cariverona Foundation
  19. Education Ministry (MIUR)
  20. Norway: Norwegian Research Council [214123]
  21. Norway: Western Norway Regional Health Authorities grant [911631]
  22. Norway: Bergen Medical Research Foundation
  23. Spain: Fondo de Investigacion Sanitaria [PS09/02457, PS09/00716, PS09/01511, PS09/02185, PS09/03190]
  24. Spain: Servicio Andaluz de Salud
  25. Spain: Sociedad Espanola de Neumologia y Cirurgia Toracica [SEPAR 1001/2010]
  26. Galdakao-Fondo de Investigacion Sanitaria [FIS 09/01511]
  27. Huelva-Fondo de Investigacion Sanitaria [FIS PS09/02185]
  28. Huelva-Servicio Andaluz de Salud
  29. Oviedo-Fondo de Investigacion Sanitaria [FIS PS09/03190]
  30. Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa 2019-2023 Program [CEX2018-000806-S]
  31. Generalitat de Catalunya through the CERCA Program
  32. Sweden: Swedish Heart and Lung Foundation
  33. Sweden: Swedish Asthma and Allergy Association
  34. Sweden: Swedish Association against Lung and Heart Disease
  35. Sweden: Swedish Research Council for Health, Working Life and Welfare (FORTE)
  36. Swedish Council for Working Life and Social Research
  37. Vasterbotten County Council ALF grant
  38. Switzerland: The Swiss National Science Foundation [33CSCO-134276/1, 33CSCO-108796, 3247BO-104283, 3247BO-104288, 3247BO-104284, 3247-065896, 3100-059302, 3200-052720, 3200-042532, 4026-028099]
  39. Switzerland: Federal Office for Forest, Environment and Landscape
  40. Switzerland: Federal Office of Public Health
  41. Switzerland: Federal Office of Roads and Transport
  42. Switzerland: canton government of Aargan
  43. Switzerland: canton government of Basel-Stadt
  44. Switzerland: canton government of Basel-Land
  45. Switzerland: canton government of Geneva
  46. Switzerland: canton government of Luzern
  47. Switzerland: canton government of Ticino
  48. Switzerland: canton government of Valais
  49. Switzerland: canton government of Zurich
  50. Switzerland: Swiss Lung League
  51. Switzerland: Lung Leagues of the canton Basel Stadt/Basel
  52. Switzerland: Lung Leagues of the canton Landschaft
  53. Switzerland: Lung Leagues of the canton Geneva
  54. Switzerland: Lung Leagues of the canton Ticino
  55. Switzerland: Lung Leagues of the canton Valais
  56. Switzerland: Lung Leagues of the canton Zurich
  57. Switzerland: SUVA
  58. Switzerland: Freiwillige Akademische Gesellschaft
  59. Switzerland: UBS Wealth Foundation
  60. Switzerland: Talecris Biotherapeutics GmbH
  61. Switzerland: Abbott Diagnostics
  62. Switzerland: European Commission [018996]
  63. Switzerland: Wellcome Trust [WT 084703MA]
  64. UK: Medical Research Council [92091]
  65. National Institute for Health Research through the Primary Care Research Network

向作者/读者索取更多资源

In a multi-center population-based study, an independent association between upper airway inflammatory disorders (UAID) and elevated fractional exhaled nitric oxide (FeNO) levels was found. There was a significant interaction with perennial sensitization and asthma, highlighting the concept of united airway disease.
Background Fractional exhaled nitric oxide (FeNO) is a well-known marker of type-2 inflammation. FeNO is elevated in asthma and allergic rhinitis, with IgE sensitization as a major determinant. Objective We aimed to see whether there was an independent association between upper airway inflammatory disorders (UAID) and FeNO, after adjustment for asthma and sensitization, in a multi-centre population-based study. Methods A total of 741 subjects with current asthma and 4155 non-asthmatic subjects participating in the second follow-up of the European Community Respiratory Health Survey (ECRHS III) underwent FeNO measurements. Sensitization status was based on measurement of IgE against airborne allergens; information on asthma, UAID and medication was collected through interview-led questionnaires. Independent associations between UAID and FeNO were assessed in adjusted multivariate regression models and test for interaction with perennial sensitization and asthma on the relation between UAID and FeNO were made. Results UAID were associated with higher FeNO after adjusting for perennial sensitization, asthma and other confounders: with 4.4 (0.9-7.9) % higher FeNO in relation to current rhinitis and 4.8 (0.7-9.2) % higher FeNO in relation to rhinoconjunctivitis. A significant interaction with perennial sensitization was found in the relationship between current rhinitis and FeNO (p = .03) and between rhinoconjunctivitis and FeNO (p = .03). After stratification by asthma and perennial sensitization, the association between current rhinitis and FeNO remained in non-asthmatic subjects with perennial sensitization, with 12.1 (0.2-25.5) % higher FeNO in subjects with current rhinitis than in those without. Conclusions & Clinical Relevance Current rhinitis and rhinoconjunctivitis was associated with higher FeNO, with an interaction with perennial sensitization. This further highlights the concept of united airway disease, with correlations between symptoms and inflammation in the upper and lower airways and that sensitization needs to be accounted for in the relation between FeNO and rhinitis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据